April 28, 2017
Recommended Topic Related To:


"Prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) or acetaminophen modestly increases the risk for hearing loss in older women, a prospective analysis of data from the Nurses' Health Study (NHS) I has found. A similar relationship wa"...



Side Effects


The following serious adverse reactions are discussed elsewhere in the labeling:

The most common adverse reactions (reported in greater than 20%) are paresthesia and pruritus. The most commonly reported reasons for discontinuation are paresthesia and cough.

Clinical Trials Experience

Adverse reactions presented in this section are derived from 332 patients in 3 controlled clinical trials in patients undergoing colonoscopy or flexible bronchoscopy and 123 patients in one open-label study in patients undergoing minor procedures. Patients enrolled in the studies who received the standard or modified dosing regimen included males and females, ≥ 18 years of age and ranging from healthy (359/455 [79%] ASA P1 or P2) to those with severe systemic disease (96/455 [21%] ASA P3 or P4). Of the 455 patients enrolled, 345 (76%) were ≥ 18 to < 65 years of age and 110 (24%) were ≥ 65 years of age. Adverse reactions are reported for patients who received the standard or the modified dosing regimen [see DOSAGE AND ADMINISTRATION]. The majority of procedures were less than thirty minutes in duration. All patients in these studies received 50 mcg fentanyl citrate intravenously as premedication, and some of the patients received additional 25 mcg fentanyl citrate supplemental doses. Adverse reactions occurring in ≥ 2% of patients in these studies are presented in Table 3.

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not accurately reflect the rates observed in practice.

Table 3. Common Adverse Reactions for Patients Receiving the Standard or Modified Dosing Regimen (Reactions Occurring at a Rate ≥ 2%)

Reaction Term Colonoscopy
Minor Procedures
n (%)
Gastrointestinal disorders
  Nausea 0 5(4) 2(1)
  Vomiting 0 4(3) 0
Injury, poisoning, and procedural complications
  Procedural Pain 0 0 3(2)
Nervous system disorders
  Paresthesiaa 135(74) 77 (63) 78 (52)
  Headache 1 (1) 3(2) 1(1)
Respiratory, thoracic, and mediastinal disorders
  Hypoxemia 3(2) 1 (1) 16(11)
Skin and subcutaneous tissue disorders
  Pruritusb 30(16) 34 (28) 24(16)
Vascular disorders
  Hypotension 4(2) 4(3) 10(7)
a Paresthesia includes the following terms: Paresthesia genital male; Burning sensation; Genital burning sensation; Vaginal burning sensation; Skin burning sensation; Genital pain (reported as burning); Perineal pain (reported as burning); Anal discomfort (reported as burning); Chest pain (reported as burning); Ear discomfort (reported as burning); Nasal discomfort (reported as burning); Buttock pain (reported as stinging); Groin pain (reported as stinging); Pain (reported as stinging); Sensory disturbance (reported as non-specific sensation in pubic area).
b Pruritus includes the following terms: Genital pruritus female; Genital pruritus male; Pruritus genital; Pruritus ani; Pruritus generalized.

Paresthesias (including burning, tingling, stinging) and/or pruritus, usually manifested in the perineal region, were the most frequently recorded adverse reactions in clinical trials. Paresthesias and pruritus generally occurred within 5 minutes after administration of the initial dose of LUSEDRA (fospropofol disodium injection) and were generally transient and mild to moderate in intensity. The pharmacologic basis of these sensory phenomena is unknown. No pretreatments, including the use of nonsteroidal anti-inflammatory drugs, opioids, or lidocaine, are known to have an effect on or to reduce the incidence of these sensations.

Sedation-related adverse reactions were experienced at the following rates for subjects receiving the standard or modified LUSEDRA (fospropofol disodium injection) dosing regimen: 20/455 (4%) hypoxemia, 18/455 (4%) hypotension, 1/455 ( < 1%) apnea. A greater rate of sedation-related adverse reactions necessitating intervention was observed in patients undergoing bronchoscopy compared with colonoscopy and minor surgical procedures. In the colonoscopy studies, 5/183 (3%) patients were ASA P3. In the minor surgical procedures study, 23/123 (19%) patients were ASA P3 or P4. In the flexible bronchoscopy study, 68/150 (46%) patients were ASA P3 or P4. The type and incidence of airway assistance interventions required for patients who experienced sedation-related adverse reactions are presented in Table 4.

Table 4. Patient Incidence of Airway Management Events

  Healthy Subjectsa
6 mg/kg
n (%)
6.5 mg/kg (or modified dosing regimen)
n (%)
Minor Proceduresb
6.5 mg/kg (or modified dosing regimen)
n (%)
Flexible Bronchoscopyb
6.5 mg/kg (or modified dosing regimen)
n (%)
Increased O2 0 0 0 21 (14)
Patient Repositioning 0 0 0 2(1)
Verbal Stimulation 0 2(1) 1 (1) 5(3)
Tactile Stimulation 0 0 0 3(2)
Face Mask (100% O2) 0 0 0 1 (1)
Jaw Thrust 0 0 0 2(1)
Chin Lift 0 0 1 (1) 3(2)
Nasal Trumpet 0 0 0 0
Oral Airway 0 0 0 0
Suction 0 0 0 2(1)
Manual Ventilation (bag valve mask) 0 0 0 1 (1)
Mechanical Ventilation 0 0 0 0
a No concomitant medications administered. All subjects were healthy volunteers.
b All patients premedicated with 50 mcg fentanyl citrate. Subjects ranged from healthy to those with severe systemic disease that is a constant threat to life (ASA P1 to P4).

Adverse Reactions in Prolonged Exposure in Adults

The safety of LUSEDRA (fospropofol disodium injection) for continuous sedation has not been established and therefore its use is not recommended. LUSEDRA (fospropofol disodium injection) was administered to 38 intubated and mechanically ventilated patients in postoperative and intensive care settings. An occurrence of nonsustained ventricular tachycardia was observed as a serious adverse reaction in one patient in the study. Another patient with acute myeloid leukemia with renal and hepatic insufficiency experienced a further increase in plasma formate concentration from a baseline of 66 mcg/mL to a post-dose level of 212 mcg/mL after a 12-hour infusion. The clinical significance of these findings is unknown.

Read the Lusedra (fospropofol disodium injection) Side Effects Center for a complete guide to possible side effects


LUSEDRA (fospropofol disodium injection) may produce additive cardiorespiratory effects when administered with other cardiorespiratory depressants such as sedative-hypnotics and narcotic analgesics.

Drug Abuse And Dependence

Controlled Substance

LUSEDRA (fospropofol disodium injection) is a Schedule IV controlled substance.


No formal studies of the abuse potential of LUSEDRA (fospropofol disodium injection) have been conducted. Administration of LUSEDRA (fospropofol disodium injection) resulted in euphoria in a small number of subjects who received intravenous or oral dosing.


No formal studies of dependence have been conducted.

Read the Lusedra Drug Interactions Center for a complete guide to possible interactions

This monograph has been modified to include the generic and brand name in many instances.

Last reviewed on RxList: 12/29/2016

Side Effects

Additional Lusedra Information

Report Problems to the Food and Drug Administration


You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.

Chronic Pain/Back Pain

Find tips and advances in treatment.

Health Resources
Use Pill Finder Find it Now See Interactions

Pill Identifier on RxList

  • quick, easy,
    pill identification

Find a Local Pharmacy

  • including 24 hour, pharmacies

Interaction Checker

  • Check potential drug interactions
Search the Medical Dictionary for Health Definitions & Medical Abbreviations